Document Detail

Preparation and in vitro/in vivo evaluation of microparticle formulations containing meloxicam.
MedLine Citation:
PMID:  22101966     Owner:  NLM     Status:  MEDLINE    
In this study, we have formulated chitosan-coated sodium alginate microparticles containing meloxicam (MLX) and aimed to investigate the correlation between in vitro release and in vivo absorbed percentages of meloxicam. The microparticle formulations were prepared by orifice ionic gelation method with two different sodium alginate concentrations, as 1% and 2% (w/v), in order to provide different release rates. Additionally, an oral solution containing 15 mg of meloxicam was administered as the reference solution for evaluation of in vitro/in vivo correlation (ivivc). Following in vitro characterization, plasma levels of MLX and pharmacokinetic parameters [elimination half-life (t(1/2)), maximum plasma concentration (C(max)), time for C(max) (t(max))] after oral administration to New Zealand rabbits were determined. Area under plasma concentration-time curve (AUC(0-∞)) was calculated by using trapezoidal method. A linear regression was investigated between released% (in vitro) and absorbed% (in vivo) with a model-independent deconvolution approach. As a result, increase in sodium alginate content lengthened in vitro release time and in vivo t(max) value. In addition, for ivivc, linear regression equations with r(2) values of 0.8563 and 0.9402 were obtained for microparticles containing 1% and 2% (w/v) sodium alginate, respectively. Lower prediction error for 2% sodium alginate formulations (7.419 ± 4.068) compared to 1% sodium alginate formulations (9.458 ± 5.106) indicated a more precise ivivc for 2% sodium alginate formulation.
Hakan Eroglu; Nihan Burul-Bozkurt; Serdar Uma; Levent Oner
Related Documents :
25136816 - Plasma anti-mullerian hormone: an endocrine marker for in vitro embryo production from...
24895696 - Antioxidant status in patients with psoriasis.
24329006 - Serum anti-helicobacter pylori immunoglobulin g titer correlates with grade of histolog...
23519176 - Current daily glucocorticoid use and serum creatinine levels are associated with lower ...
3097236 - Effects of an lh-releasing hormone antagonist on the secretion of lh, fsh, prolactin an...
16372826 - Penetration of orally administered prulifloxacin into human lung tissue.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-11-19
Journal Detail:
Title:  AAPS PharmSciTech     Volume:  13     ISSN:  1530-9932     ISO Abbreviation:  AAPS PharmSciTech     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-02-21     Completed Date:  2012-10-30     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  100960111     Medline TA:  AAPS PharmSciTech     Country:  United States    
Other Details:
Languages:  eng     Pagination:  46-52     Citation Subset:  IM    
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Sihhiye, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chemistry, Pharmaceutical
Cross-Over Studies
Drug Evaluation, Preclinical / methods
Thiazines / administration & dosage,  chemistry*,  metabolism*
Thiazoles / administration & dosage,  chemistry*,  metabolism*
Reg. No./Substance:
0/Thiazines; 0/Thiazoles; 71125-38-7/meloxicam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Solubility of drugs in aqueous polymeric solution: effect of ovalbumin on microencapsulation process...
Next Document:  Investigating the use of liquisolid compacts technique to minimize the influence of pH variations on...